Keyword: Servier

Research & Innovation

Artificial Intelligence for New Drug Design

16.09.2021 -

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.


Servier Buys Denmark’s Symphogen

16.04.2020 - French pharma Servier has agreed to buy Danish biotech Symphogen for an undisclosed sum. Headquartered in Copenhagen, Symphogen has created an antibody discovery and research...


Servier Gets Blood Cancer Drug from CTI BioPharma

19.11.2019 - French drugmaker Servier has acquired blood cancer treatment Pixuvri from US-based CTI BioPharma for an undisclosed sum. Pixuvri is a treatment for adults with multiply relapsed or...


Shire sells Oncology Portfolio to Servier

04.09.2018 - Ahead of its acquisition by Japan’s Takeda Pharmaceutical, Ireland-domiciled, London-listed and US-focused Shire has completed the sale of its oncology portfolio with $262 million...


Shire Sells Oncology Unit to Servier for $2.4 Billion

18.04.2018 - Ireland-based drugs giant Shire is selling its oncology business to France’s Servier in a deal worth $2.4 billion. The sale comes just as Japan’s Takeda Pharmaceutical was reported...


GSK Fined for Blocking Copies of Seroxat

15.02.2016 - Major UK drugs firm GlaxoSmithKline (GSK) has been fined more than £37 million by the Competition and Markets Authority (CMA) for anti-competitive behavior relating to generic...


Lundbeck, Merck KGaA and Others Fined for Blocking Rival Drugs

20.06.2013 - European antitrust regulators fined nine drugmakers, including Denmark's Lundbeck, a total of €146 million ($195 million) for blocking the supply of a cheaper anti-depressant to...


EU to Fine Lundbeck, Others for Blocking Generic Drugs

03.06.2013 - A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said...